NCT06758544View on ClinicalTrials.gov

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

November 30, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

Oncolytic virus VRT106

VRT106, IV

DRUG

Chemotherapy

21 days/cycle, administered up to 6 cycles

Trial Locations (1)

Unknown

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Guangzhou Virotech Pharmaceutical Co., Ltd.

INDUSTRY

lead

Guangdong Provincial People's Hospital

OTHER